News and Press Releases
Phesi launches self-service Investigator Site Profiler solution to enhance precision of investigator site selection
Solution benefits clinical development and medical affairs groups – eliminating 20%-30% of investigator sites where there isn’t sufficient data to ensure performance 2 April 2025 -- Massachusetts, US -- Phesi,...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 2, 2025
Navigo Proteins Announces Strategic R&D Collaboration with SCK CEN to Develop Targeted Radiotheranostics
1 April 2025 -- Halle, Germany and Mol, Belgium -- Navigo Proteins GmbH, a leader in precision medicine and next-generation radiotheranostics, today announced a strategic research collaboration with SCK CEN,...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: April 1, 2025
Domain Therapeutics to Present Data on its GPCR Lead Programs at AACR Annual Meeting 2025
Presentation of Phase I clinical results from DT-9081, an EP4 receptor antagonist, and preclinical data on DT-7012, a Treg depleting anti-CCR8 antibody Preclinical findings highlight immuno-oncology breakthrough properties for its...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 1, 2025
PARC D'INNOVATION 220 Boulevard Gonthier D'Andernach 67400 Strasbourg - Illkirch - France
OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod
Urcosimod in Phase 2 clinical trial for Neuropathic Corneal Pain shown to have Long-Term Stability Urcosimod stable in single-use ampoules for more than 2½ years FDA requires drug to show...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 31, 2025
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
Rybelsus reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic kidney disease in the SOUL cardiovascular outcomes trial Data were...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 29, 2025
Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results in adults with elevated eosinophils Approval marks the first new treatment...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: March 28, 2025
WCG ClinSphere Total Feasibility Releases Self-Serve Capabilities that Optimize Clinical Trial Site Selection
27 March 2025 -- North Carolina, US -- WCG, a global leader in providing solutions that measurably improve and accelerate clinical research, today announced the launch of WCG ClinSphere™ Total Feasibility's...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 27, 2025
Alys Pharmaceuticals Announces Dosing of First Patient in Phase IIa Trial of ALY-101 for Alopecia Areata
Unique siRNA platform, developed with Nobel Prize Laureate Craig Mello, offers potential for treating multiple dermatology indications ALY-101 is formulated as an intradermal injectable for the treatment of Alopecia Areata...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 27, 2025
100 Northern Avenue Boston Massachusetts 02210, United States
Cleerly to Present Late-Breaking Clinical Trial Results on Cardiovascular Risk in Women at ACC 25
Cleerly to Present Late-Breaking Findings and Participate in Key ACC 25 Sessions 27 March 2025 -- Illinois, US -- Cleerly, the leader in cardiovascular AI imaging, announces its participation in...
Category: Clinical Trials, Other, Pharmaceutical
Posted: March 27, 2025
RYBREVANT (amivantamab) plus LAZCLUZE (lazertinib) demonstrates significant overall survival benefit in patients with EGFR-mutated advanced non-small cell lung cancer versus osimertinib
Median overall survival not yet reached with a projected improvement of more than one year versus osimertinib 26 March 2025 -- Beerse, Belgium -- Janssen-Cilag International NV, a Johnson &...
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: March 26, 2025
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Ryvu Therapeutics to Present Preclinical Data on Synthetic Lethality at the 2025 AACR Annual Meeting
KRAS-specific synthetic lethal targets identified through Ryvu's ONCO Prime platform show promising potential for new therapeutic options for colorectal cancer (CRC) patients RVU305, a potentially best-in-class, brain-permeable MTA-cooperative PRMT5 inhibitor,...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 26, 2025
R&D Center for Innovative Drugs Leona Henryka Sternbacha 2 30-394 Kraków, Poland
iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025
25 March 2025 -- Massachusetts, US, and Gosselies, Belgium -- iTeos Therapeutics, Inc, a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: March 25, 2025
SGLT2 HYPE – a guideline-relevant, clinical trial aiming to establish SGLT2 inhibitors as a new standard in hypertension therapy, ultimately addressing one of the leading causes of premature mortality in Germany and Europe
25 March 2025 -- Lübeck, Germany -- On January 1, 2025, the European research project SGLT2 HYPE (SGLT2 inhibition for cardiovascular reduction in HYPErtension) was officially launched, receiving €6.99 million...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 25, 2025
Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis
If approved, tolebrutinib would be the first and only brain-penetrant BTK inhibitor to both treat non-relapsing secondary progressive multiple sclerosis (MS) and slow disability accumulation independent of relapse activity Tolebrutinib...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 25, 2025
Galimedix Therapeutics to present positive pre-clinical data with amyloid beta aggregation modulator in development for oral Alzheimer’s disease treatment at AD/PD 2025 Conference
Data show positive impact of small molecule GAL-201 on Aβ-induced toxicity, caused by various Aβ isoforms: beneficial effects on synaptic plasticity and neuroinflammation 24 March 2025 -- Maryland, US and...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 24, 2025
